Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
17-β Estradiol regulates proglucagon-derived peptide secretion in mouse and human α- and L cells
Sandra Handgraaf, Rodolphe Dusaulcy, Florian Visentin, Jacques Philippe, Yvan Gosmain
Sandra Handgraaf, Rodolphe Dusaulcy, Florian Visentin, Jacques Philippe, Yvan Gosmain
View: Text | PDF
Research Article Endocrinology Metabolism

17-β Estradiol regulates proglucagon-derived peptide secretion in mouse and human α- and L cells

  • Text
  • PDF
Abstract

Clinical and experimental data indicate a beneficial effect of estrogens on energy and glucose homeostasis associated with improved insulin sensitivity and positive effects on insulin secretion. The aim of the study was to investigate the impact of estrogens on proglucagon-producing cells, pancreatic α cells, and enteroendocrine L cells. The consequences of sexual hormone deprivation were evaluated in ovariectomized mice (ovx). Ovx mice exhibited impaired glucose tolerance during oral glucose tolerance tests (OGTT), which was associated with decreased GLP-1 intestinal and pancreatic secretion and content, an effect that was reversed by estradiol (E2) treatment. Indeed, E2 increased oral glucose–induced GLP-1 secretion in vivo and GLP-1 secretion from primary culture of mouse and human α cells through the activation of all 3 estrogen receptors (ERs), whereas E2-induced GLP-1 secretion from mouse and human intestinal explants occurred only by ERβ activation. Underlying the implication of ERβ, its selective agonist WAY20070 was able to restore glucose tolerance in ovx mice at least partly through plasma GLP-1 increase. We conclude that E2 directly controls both α- and L cells to increase GLP-1 secretion, in addition to its effects on insulin and glucagon secretion, highlighting the potential beneficial role of the estrogenic pathway and, more particularly, of ERβ agonists to prevent type 2 diabetes.

Authors

Sandra Handgraaf, Rodolphe Dusaulcy, Florian Visentin, Jacques Philippe, Yvan Gosmain

×

Figure 6

Estrogen receptors mediate estradiol effects in α- and L cells.

Options: View larger image (or click on image) Download as PowerPoint
Estrogen receptors mediate estradiol effects in α- and L cells.
Sorted α...
Sorted α- and L cells isolated from 13-week-old female mice ovariectomized for a week and GLUTag cells were studied for the expression of estrogen receptors (ERs) (A). GLP-1 releases during 2 hours in fresh medium were quantified in supernatants relative to contents of purified α cells (n = 7 experiments in each group) (B), of dissociated mixed cells from small intestine (jejunum/ileum) (n = 6 experiments in each group) (C), and of GLUTag cell cultures (n = 5 experiments in each groups) (D), cultured during 48h hours with vehicle (DMSO) or the several SERMs (E2, PPT, WAY, and G1 at 1 × 10–8 mol/l). One-way ANOVA with the Dunnett’s multiple comparison post test. *P ≤ 0.05 for vehicle- vs. E2 agonist–treated cells.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts